EXACT SCIENCES CORPEXAS

EXACT SCIENCES CORP Revenue Disclosure

10-KFiled Feb 13, 20262 min read
REVENUE
 The following table presents the Company’s revenues disaggregated by revenue source:
Year Ended December 31,
(In thousands)202520242023
Screening
Medicare Parts B & C$955,075 $776,155 $701,400 
Commercial1,323,216 1,118,338 992,244 
Other251,575 209,375 171,057 
Total Screening2,529,866 2,103,868 1,864,701 
Precision Oncology
Medicare Parts B & C$196,468 $187,948 $188,689 
Commercial196,170 190,595 181,318 
International223,844 189,092 153,277 
Other100,642 87,364 105,826 
Total Precision Oncology717,124 654,999 629,110 
COVID-19 Testing$— $— $5,955 
Total$3,246,990 $2,758,867 $2,499,766 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics, LLC tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests. The Company discontinued its COVID-19 testing operations in the second quarter of 2023.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1%, 1%, and 2% of revenue recorded in the Company’s consolidated statement of operations for the years ended December 31, 2025, 2024, and 2023, respectively.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s consolidated balance sheets, was not significant as of December 31, 2025 and 2024.
Revenue recognized for the years ended December 31, 2025 and 2024, which was included in the deferred revenue balance at the beginning of the year was not significant.

Historical Timeline

Fiscal YearFiled
2025Feb 13, 2026Showing above
2024Feb 19, 2025
2023Feb 21, 2024
2022Feb 21, 2023
2021Feb 22, 2022
2020Feb 16, 2021

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesFair ValuePP&EGoodwill & IntangiblesSegmentsDebtCommitmentsStock CompensationNew StandardsPay vs Performance